Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1 , plus 5-FU day 1 and 8 , and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8 , cyclophosphamide day 1 and methotrexate day 1 (AFCM). These courses were repeated every 21 days. The response rate was 44/105(42%) AF, 44/103(43%) AFC and 52/105 (49%) AFCM. The length of response was 22, 33 and 35 weeks, respectively, for AF, AFC and AFCM (P = 0.21). The median survival, 64 weeks, was equal in all three limbs. The major toxicity was leukopenia. Twenty-eight percent developed a WBC of less than 2 ,OOO/pl, which resulted in seven deaths (2.2%).
Cancer 4 1 : 2 0 78-2083, 19 78.
DRIAMYCIN IS ONE OF THE MOST EFFECTIVE
A single chemotherapeutic agents in the treatment of metastatic breast cancer with remission rates, complete plus partial, ranging from 28 to 43%.3j'0The enthusiasm for the use of adriamycin as a single agent has been terripered somewhat by the relatively short length of remissions. A previous study by the Southwest O ncology Group' showed a maintained remission of 4 months using adriamycin alone compared to 10 months using a combination of cyclophosphamide, vincristine, methotrexate, 5-FU and prednisone (COMFP). T h e regimens of this study combine one or more of the drugs from the Presented in part .4SCO,